Metyrapone (2-methyl-1,2-bis-(3-pyridyl)-1-propanone, SU-4885) when administered to normal women decreases urinary oestrogen excretion (Földes, Koref, Fehér & Steczek, 1964; Sfikakis, Ikkos & Diamandopoulos, 1967) whereas in women with the polycystic ovary syndrome urinary oestrogen excretion is increased (Sfikakis et al. 1967). On the other hand, metyrapone inhibits oestrogen production from androgen precursors in the isolated organ (Giles & Griffiths, 1964; Koref, Steczek, Fehér & Földes, 1966) as well as oestrogen production in the intact animal (Matsumoto, Kotoh, Miyata & Kurachi, 1965).
In order to study further the action of metyrapone on oestrogen production in vivo it was thought that the uterus of female rats after the administration of dehydroepiandrosterone (DHA) would be a suitable model, in view of the oestrogen-like effect of DHA on the uterus of immature female rats described by Harper (1969).
The study included 43 prepubertal female rats (Wistar, aged 29–35 days on day of autopsy) and 46
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 0 | 0 | 0 |
| PDF Downloads | 0 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
